Annual Drug Patent Expirations for TAGRISSO
Tagrisso is a drug marketed by Astrazeneca and is included in one NDA. It is available from one supplier. There are three patents protecting this drug.
Drug patent litigation for TAGRISSO.
This drug has one hundred and forty-four patent family members in forty-four countries.
The generic ingredient in TAGRISSO is osimertinib mesylate. One supplier is listed for this compound. Additional details are available on the osimertinib mesylate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
